Change of Circulating Vascular Endothelial Growth Factor Level and Reduction of Anhedonia Are Associated in Patients With Major Depressive Disorder Treated With Repetitive Transcranial Magnetic Stimulation.
anhedonia
antidepressant
brain stimulation
depression
treatment resistant depression
Journal
Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006
Informations de publication
Date de publication:
2022
2022
Historique:
received:
01
11
2021
accepted:
27
04
2022
entrez:
17
6
2022
pubmed:
18
6
2022
medline:
18
6
2022
Statut:
epublish
Résumé
Vascular endothelial growth factor (VEGF) has been implicated in mediating the effect of antidepressant therapies as it plays a significant role in the neurogenesis. Anhedonia, an endophenotype of major depressive disorder (MDD), is related to the dorsolateral prefrontal cortex, the major focus of brain stimulation in MDD. The aim of our study was to analyze the change of serum VEGF level after rTMS treatment in association with anhedonia. A dataset of 17 patients with TRD who were treated with antidepressants and bilateral rTMS for 2 × 5 days was analyzed. Depression was measured by the Montgomery-Asberg Depression Scale (MADRS) and anhedonia by the Snaith-Hamilton Pleasure Scale (SHAPS) for monitoring the symptom changes. The serum VEGF levels and symptoms were assessed on the first (V1), on the 14th (V2), and on the 28th day (V3). The level of VEGF was measured by ELISA assay. There was no significant association between MADRS scores and serum VEGF levels at any timepoint. The decrease in the SHAPS score was significantly associated with the increase in VEGF level between V1 and V2 ( Our results suggest that serum VEGF can be sensitive to the changes of anhedonia during rTMS treatment. Considering that the most widely used depression scales are not applicable for the assessment of anhedonia, measurement of anhedonia in rTMS treatment studies of patients with TRD can be suggested as more appropriate data on distinct pathogenic pathways and specific biomarkers of the disorder.
Identifiants
pubmed: 35711587
doi: 10.3389/fpsyt.2022.806731
pmc: PMC9193814
doi:
Types de publication
Journal Article
Langues
eng
Pagination
806731Informations de copyright
Copyright © 2022 Elemery, Kiss, Dome, Pogany, Faludi and Lazary.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Biol Psychiatry. 2010 Mar 1;67(5):439-45
pubmed: 20034615
Psychiatry Res. 2020 Oct;292:113319
pubmed: 32717712
J Psychopharmacol. 2018 Oct;32(10):1067-1074
pubmed: 30260258
J Affect Disord. 2019 Jun 15;253:449-453
pubmed: 31103810
Acta Psychiatr Scand. 2014 Jun;129(6):461-6
pubmed: 23957507
Biol Psychiatry. 2014 Aug 1;76(3):176-85
pubmed: 24388670
Psychiatry Investig. 2020 Mar;17(3):207-221
pubmed: 32209966
Neurosci Biobehav Rev. 2021 May;124:54-62
pubmed: 33482243
Br J Psychiatry. 2009 Sep;195(3):211-7
pubmed: 19721109
J Am Acad Child Adolesc Psychiatry. 2012 Apr;51(4):404-11
pubmed: 22449646
Front Psychiatry. 2018 Aug 23;9:386
pubmed: 30190686
Mol Neurobiol. 2019 Jun;56(6):4364-4380
pubmed: 30317434
Psychiatr Hung. 2020;35(2):146-174
pubmed: 32191220
Int J Mol Sci. 2018 Sep 23;19(10):
pubmed: 30249029
Behav Brain Res. 2012 Feb 14;227(2):440-9
pubmed: 21536078
Biol Psychiatry. 2007 Dec 1;62(11):1208-16
pubmed: 17573044
Am J Psychiatry. 2020 May 1;177(5):435-446
pubmed: 32160765
Biol Psychiatry. 2006 Jun 15;59(12):1116-27
pubmed: 16631126
Clin Neurophysiol. 2021 Feb;132(2):429-448
pubmed: 33465534
Transl Psychiatry. 2019 Sep 3;9(1):217
pubmed: 31481688
Neuroreport. 2020 Jan 27;31(2):125-130
pubmed: 31895747
Br J Psychiatry. 1979 Apr;134:382-9
pubmed: 444788
J Psychiatr Res. 2020 Jul;126:92-97
pubmed: 32428748
J Affect Disord. 2013 Jan 25;144(3):269-73
pubmed: 23021824
Mediators Inflamm. 2019 Nov 19;2019:9130868
pubmed: 31827384
CNS Neurosci Ther. 2019 Nov;25(11):1229-1236
pubmed: 31638332
Eur Arch Psychiatry Clin Neurosci. 2018 Dec;268(8):839-848
pubmed: 29968119
Acta Psychiatr Scand Suppl. 2004;(422):39-45
pubmed: 15330937
Neuropsychopharmacol Hung. 2019 Dec;21(4):179-186
pubmed: 32015195
Drug Dev Res. 2020 Aug;81(5):593-599
pubmed: 32173896
Aust N Z J Psychiatry. 2020 Apr;54(4):402-408
pubmed: 31823655
Brain Stimul. 2009 Jan;2(1):50-4
pubmed: 20539835
Br J Psychiatry. 1995 Jul;167(1):99-103
pubmed: 7551619
Acta Psychiatr Scand. 2017 Dec;136(6):594-606
pubmed: 28975998